NYSE$USNA
USANA Health Sciences Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
USANA Health Sciences reported its financial results for the fourth quarter and full fiscal year ended December 28, 2024, including the impact of the Hiya Health Products acquisition.
USANA Health Sciences reported a decrease in net sales and net earnings for the fourth quarter of 2024 compared to the same period in 2023. Diluted EPS also saw a significant decline. The company completed the acquisition of a controlling stake in Hiya Health Products, which contributed approximately $2 million to net sales in Q4 2024.
- Net sales for Q4 2024 were $214 million, down from $221 million in Q4 2023.
- Net earnings for Q4 2024 were $4.5 million, a substantial decrease from $16.8 million in Q4 2023.
- Diluted EPS for Q4 2024 was $0.23, compared to $0.87 in Q4 2023.
- Adjusted diluted EPS for Q4 2024 was $0.64, down from $0.87 in Q4 2023, and Adjusted EBITDA was $25 million, down from $32 million.
Headline financials
Revenue & EPS history
USANA · Revenue · Quarterly
$214M
Forward guidance
USANA provided its fiscal year 2025 outlook, expecting consolidated net sales between $920 million and $1.0 billion, and diluted EPS between $1.50 and $2.20. The outlook includes the impact of the Hiya acquisition and certain transaction-related expenses.
Tailwinds
- Expected consolidated net sales growth of 8% - 17% for fiscal year 2025.
- Hiya is expected to contribute $145 million to $160 million in net sales, reflecting a year-over-year growth of +29% to +42%.
- Fiscal 2025 is a 53-week year, including one additional week of sales compared to fiscal 2024.
- Growth strategy for direct sales business centered on Associate sales force and resources for sustainable active customer growth.
- Hiya's strategic priorities include capitalizing on recent product launches and expanding strategic partnerships.
Headwinds
- Net earnings are projected to be between $29 million and $41 million, lower than FY 2024.
- Diluted EPS is projected to be between $1.50 and $2.20, lower than FY 2024.
- Outlook includes certain transaction-related expenses and integration costs for the Hiya acquisition.
- Purchase price allocation for Hiya includes significant intangible assets with material amortization expense, impacting reported results.
- Outlook does not reflect potential increased costs of proposed tariffs on the business.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+2.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+1.6%
Avg return
30 days after
58%
37 / 64 earnings
Positive
+39.2%
Q2 2015
Best reaction
-24.1%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | -9.7% | -7.0% | |
| Q3 2025 | -1.6% | -2.8% | -6.0% | |
| Q2 2025 | +4.1% | +0.8% | +1.5% | |
| Q1 2025 | +4.9% | +13.6% | +21.4% | |
| Q4 2024 | +3.9% | -6.2% | -13.1% | |
| Q3 2024 | +4.4% | +5.0% | +12.3% | |
| Q2 2024 | -3.7% | -7.7% | -14.6% | |
| Q1 2024 | +6.0% | +6.0% | +8.7% | |
| Q4 2023 | +7.1% | +9.6% | +4.6% | |
| Q3 2023 | -16.7% | -17.7% | -13.8% | |
| Q2 2023 | +6.5% | +2.1% | -0.3% | |
| Q1 2023 | +4.9% | +2.5% | -4.4% | |
| Q4 2022 | +4.7% | +4.0% | +2.4% | |
| Q3 2022 | -0.2% | -3.0% | -6.5% | |
| Q2 2022 | +1.1% | +1.4% | -0.5% | |
| Q1 2022 | -3.6% | -2.6% | -10.4% | |
| Q4 2021 | -8.4% | -5.2% | -10.1% | |
| Q3 2021 | -8.0% | -3.4% | +1.3% | |
| Q2 2021 | -2.3% | -6.8% | -6.9% | |
| Q1 2021 | -7.7% | -6.4% | +9.4% | |
| Q4 2020 | +15.7% | +6.3% | +16.4% | |
| Q3 2020 | +5.1% | +10.7% | -3.5% | |
| Q2 2020 | -6.4% | -12.4% | -8.8% | |
| Q1 2020 | +17.5% | +25.2% | +23.8% | |
| Q4 2019 | +25.3% | +28.1% | +15.7% | |
| Q3 2019 | +11.5% | +4.8% | +1.8% | |
| Q2 2019 | +0.3% | +6.1% | +5.7% | |
| Q1 2019 | +9.4% | +2.2% | -12.9% | |
| Q4 2018 | -11.4% | -6.5% | -18.1% | |
| Q3 2018 | +3.5% | +2.7% | +13.0% | |
| Q2 2018 | +23.9% | +18.9% | +19.0% | |
| Q1 2018 | +11.6% | +10.3% | +22.2% | |
| Q4 2017 | +5.6% | +7.0% | +14.4% | |
| Q3 2017 | +12.5% | +9.7% | +10.1% | |
| Q2 2017 | -10.0% | -11.2% | -7.5% | |
| Q1 2017 | +6.5% | +13.4% | +16.4% | |
| Q4 2016 | -11.6% | -8.9% | -8.9% | |
| Q3 2016 | -8.2% | -11.5% | -13.6% | |
| Q2 2016 | +11.6% | +8.2% | +8.4% | |
| Q1 2016 | +6.2% | — | — | |
| Q4 2015 | -24.1% | — | — | |
| Q3 2015 | -11.6% | — | — | |
| Q2 2015 | +39.2% | — | — | |
| Q1 2015 | +19.2% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +26.5% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | -15.2% | — | — | |
| Q4 2013 | +18.8% | — | — | |
| Q3 2013 | -9.6% | — | — | |
| Q2 2013 | -13.3% | — | — | |
| Q1 2013 | +8.1% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2012 | +1.7% | — | — | |
| Q2 2012 | +5.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2010 | -4.2% | — | — | |
| Q4 2011 | -4.2% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2011 | -0.3% | — | — | |
| Q1 2011 | -0.3% | — | — | |
| Q3 2010 | -2.0% | — | — | |
| Q2 2010 | +4.3% | — | — | |
| Q1 2010 | +4.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro